These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 36906275)

  • 1. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.
    Hines MR; Knight TE; McNerney KO; Leick MB; Jain T; Ahmed S; Frigault MJ; Hill JA; Jain MD; Johnson WT; Lin Y; Mahadeo KM; Maron GM; Marsh RA; Neelapu SS; Nikiforow S; Ombrello AK; Shah NN; Talleur AC; Turicek D; Vatsayan A; Wong SW; Maus MV; Komanduri KV; Berliner N; Henter JI; Perales MA; Frey NV; Teachey DT; Frank MJ; Shah NN
    Transplant Cell Ther; 2023 Jul; 29(7):438.e1-438.e16. PubMed ID: 36906275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy.
    Hughes AD; Teachey DT; Diorio C
    Semin Immunopathol; 2024 Jul; 46(3-4):5. PubMed ID: 39012374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy.
    Walton ZE; Frigault MJ; Maus MV
    Expert Opin Pharmacother; 2024 Feb; 25(3):263-279. PubMed ID: 38588525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)-associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy.
    Zu C; Wu S; Zhang M; Wei G; Xu H; Cui J; Chang AH; Huang H; Hu Y
    Cytotherapy; 2023 Nov; 25(11):1167-1175. PubMed ID: 37480884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed/refractory diffuse large B-Cell lymphoma.
    Kim DW; Bukhari A; Lutfi F; Zafforoni F; Merechi F; Mustafa Ali MK; Gottlieb D; Lee ST; Kocoglu MH; Hardy NM; Yared J; Rapoport AP; Dahiya S; Law JY
    Leuk Lymphoma; 2022 Jun; 63(6):1339-1347. PubMed ID: 35045791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells.
    Lichtenstein DA; Schischlik F; Shao L; Steinberg SM; Yates B; Wang HW; Wang Y; Inglefield J; Dulau-Florea A; Ceppi F; Hermida LC; Stringaris K; Dunham K; Homan P; Jailwala P; Mirazee J; Robinson W; Chisholm KM; Yuan C; Stetler-Stevenson M; Ombrello AK; Jin J; Fry TJ; Taylor N; Highfill SL; Jin P; Gardner RA; Shalabi H; Ruppin E; Stroncek DF; Shah NN
    Blood; 2021 Dec; 138(24):2469-2484. PubMed ID: 34525183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reactions Related to CAR-T Cell Therapy.
    Miao L; Zhang Z; Ren Z; Li Y
    Front Immunol; 2021; 12():663201. PubMed ID: 33995389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recognizing, defining, and managing CAR-T hematologic toxicities.
    Rejeski K; Subklewe M; Locke FL
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):198-208. PubMed ID: 38066881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current understanding and management of CAR T cell-associated toxicities.
    Brudno JN; Kochenderfer JN
    Nat Rev Clin Oncol; 2024 Jul; 21(7):501-521. PubMed ID: 38769449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Very unusual extremely high ferritin with cytokine release syndrome in a patient with hematological malignancy after experimental chimeric antigen receptor (CAR)-T-Cell therapy.
    Hoyt R; Ye Z; Dasgupta A
    Clin Chim Acta; 2024 Jun; 559():119704. PubMed ID: 38697457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP).
    Sandler RD; Tattersall RS; Schoemans H; Greco R; Badoglio M; Labopin M; Alexander T; Kirgizov K; Rovira M; Saif M; Saccardi R; Delgado J; Peric Z; Koenecke C; Penack O; Basak G; Snowden JA
    Front Immunol; 2020; 11():524. PubMed ID: 32296434
    [No Abstract]   [Full Text] [Related]  

  • 12. CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity.
    Jess J; Yates B; Dulau-Florea A; Parker K; Inglefield J; Lichtenstein D; Schischlik F; Ongkeko M; Wang Y; Shahani S; Cullinane A; Smith H; Kane E; Little L; Chen D; Fry TJ; Shalabi H; Wang HW; Satpathy A; Lozier J; Shah NN
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37295816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.
    Kotch C; Barrett D; Teachey DT
    Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357
    [No Abstract]   [Full Text] [Related]  

  • 14. Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients.
    Ishii K; Pouzolles M; Chien CD; Erwin-Cohen RA; Kohler ME; Qin H; Lei H; Kuhn S; Ombrello AK; Dulau-Florea A; Eckhaus MA; Shalabi H; Yates B; Lichtenstein DA; Zimmermann VS; Kondo T; Shern JF; Young HA; Taylor N; Shah NN; Fry TJ
    J Clin Invest; 2020 Oct; 130(10):5425-5443. PubMed ID: 32925169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. INSPIRED Symposium Part 3: Prevention and Management of Pediatric Chimeric Antigen Receptor T Cell-Associated Emergent Toxicities.
    McNerney KO; Hsieh EM; Shalabi H; Epperly R; Wolters PL; Hill JA; Gardner R; Talleur AC; Shah NN; Rossoff J
    Transplant Cell Ther; 2024 Jan; 30(1):38-55. PubMed ID: 37821079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute kidney injury after CAR-T cell infusion.
    Rousseau A; Zafrani L
    Bull Cancer; 2024; 111(7-8):748-753. PubMed ID: 36220698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of CAR T-cell Related Toxicities: What did the Learning Curve Teach us so Far?
    Murthy HS; Yassine F; Iqbal M; Alotaibi S; Moustafa MA; Kharfan-Dabaja MA
    Hematol Oncol Stem Cell Ther; 2022 Nov; 15(3):100-111. PubMed ID: 36395496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
    Freyer CW; Porter DL
    J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
    Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
    Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing side effects: guidance for use of immunotherapies in multiple myeloma.
    Liang EC; Sidana S
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):348-356. PubMed ID: 38066898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.